If you’re looking for the best pharmaceutical companies to invest in, you should know that Oasmia Pharmaceutical AB (STO:$OASM), a Swedish company that focuses on the development of drugs within the fields of human and veterinary oncology, saw their shares gain around 2% in Stockholm trading. This increase came after Oasmia Pharmaceutical AB disclosed that they have enrolled into a new exclusive marketing and distributions deal with Indian pharmaceutical company, Hetero Group. The end goal of this agreement is to increase revenue in Russia and other Commonwealth of Independent States (CIS) markets.
Source: YouTube/Oasmia Pharmaceutical AB
Within the terms of this agreement, Hetero Group will be in charge of the marketing and circulation of Paclical in Russia as well as a number of other markets stretching over CIS markets, such as the Ukraine and Kazakhstan.
Forming a relationship with Hetero is crucial as the company has a massive distribution and sales operations in the region. Plus, Hetero will be investing its own resources into the marketing of Paclical and Oasmia products, Doxophos and Coecal. Additionally, both Oasmia and Hetero Group have signed an LOI in regards to India and South America.
Oasmia shares were trading at 3.52 Swedish kronor in Stockholm, which means that the company’s shares are up 2.33 percent.
Featured Image: facebook
